AAIC Stock Recent News

STOCKHOLM , July 31, 2025 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai presented the latest findings on lecanemab (Leqembi®) at the Alzheimer's Association International Conference (AAIC), held in Toronto, July 27 to 31. The presentations included four-year treatment data from the phase 3 Clarity AD open-label extension study, data on subcutaneous dosing and interim data from an ongoing real-world evidence study.

TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd.

-- Pre-specified analysis shows obicetrapib significantly reduced absolute levels of plasma p-tau217, a key biomarker of Alzheimer's disease pathology, in both the full analysis set (p=0.0019) and in ApoE4 carriers (p=0.0215), supporting CETP inhibition as a potential novel, upstream approach to Alzheimer's prevention –

- Zervimesine's impact on debilitating DLB behavioral symptoms highlighted in podium presentation - - Plasma p-tau217 levels can identify Alzheimer's patients most likely to benefit from zervimesine treatment - - Plasma and CSF biomarkers support zervimesine's impact on Alzheimer's disease biology -

Long-term INM-901 treatment in preclinical studies in advanced disease continues to show multi-modal activity Vancouver, British Columbia--(Newsfile Corp. - July 28, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that it is presenting new preclinical data from its INM-901 program at the upcoming Alzheimer's Association International Conference (AAIC) 2025, the world's leading forum for Alzheimer's disease ("AD") and dementia research. Data will be presented in a scientific poster entitled, " Therapeutic Potential of INM-901 in Mitigating Alzheimer's Disease Pathology: Insights from a Long-term 5xFAD Mouse Model Study ".

NAARDEN, the Netherlands and MIAMI, July 22, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (CVD) with elevated low-density lipoprotein cholesterol (LDL-C), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present full data from the prespecified Alzheimer's Disease (AD) biomarker analyses in the BROADWAY clinical trial (NCT05142722) in a late-breaking oral presentation at the Alzheimer's Association International Conference (AAIC), being held July 30, 2025 in Toronto, Canada.

NEWTON, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), will present new findings at the upcoming Alzheimer's Association International Conference (AAIC®) 2025 in Toronto. The presentations include a cost savings analysis of the use of pTau217 as a screening tool in Acumen's Phase 2 ALTITUDE-AD trial of sabirnetug as well as a nonclinical study evaluating the relative selectivity of sabirnetug to targeting AβOs versus Aβ monomers. The conference will be held July 27-31, 2025, both in-person and online.

MALVERN, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its senior management will attend the Alzheimer's Association International Conference (AAIC), taking place July 27–31, 2025, in Toronto, Canada.

We take a look at the action in preferreds and baby bonds through the third week of December and highlight some of the key themes we are watching. Preferreds rallied as Treasury yields fell, bringing year-to-date total return to around 9%. AAIC announced plans to delist and deregister its two baby bonds, citing compliance costs outweighing benefits.

U.S. equity markets extended their rebound to a third-straight week as benchmark interest rates dipped on economic data and corporate earnings reports showing a more distinct cooldown in economic activity. Gaining for a third-straight week and extending its rebound to nearly 10% since dipping into "correction territory" at the end of October, the S&P 500 gained another 2.4% this week. Lifted by the retreat in benchmark interest rates, real estate equities have roared back to life over the past three weeks. Equity REITs and Mortgage REITs each gained another 4.7%.